Ophthalmoscope Market Analysis

  • Report ID: 3999
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

zxzx

Ophthalmoscope Market Analysis

Application (Glaucoma, Retinal Tear, Diabetes)

The diabetes segment is estimated to hold 45% share of the global ophthalmoscope market in the coming years owing to the increasing cases of diabetes-induced blindness around the world. Patients suffering from diabetes have affected retina which can lead to blindness. This as a result rises the demand for ophthalmoscopes as it helps in the on-time detection and diagnosis of the disease. As per recent reports, diabetic retinopathy is accountable for nearly 4.5 % of blindness cases across the globe. By 2030, there will be around 640 million diabetics worldwide, and by 2045, the figure is expected to rise to over 78o million.

End- Users (Hospitals, Eye Clinics)

Ophthalmoscope market from the hospital segment is set to garner a notable gain in the near future. The growth of the segment is driven by the rising usage of ophthalmoscopes. Owing to the growing awareness of eye-related diseases more and more people are visiting hospitals that offer ophthalmic services to seek timely diagnosis and help in the management of eye-related conditions. This, as a result, has increased the demand for ophthalmoscopes on the hospital premises.

Our in-depth analysis of the global market includes the following segments:

     By End-User

  • Hospitals
  • Eye Clinics

     By Application

  • Glaucoma
  • Retinal Tear
  • Diabetes
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3999
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of ophthalmoscope is assessed at USD 263.52 Million.

The ophthalmoscope market size was over USD 253.76 Million in 2023 and is projected to exceed USD 422.53 Million by 2036, witnessing over 4% CAGR during the forecast period i.e., between 2024-2036. Rising cases of ocular diseases such as glaucoma, corneal opacification, and others are the major factors driving the market growth.

North America is predicted to account for the largest share of 37% by 2036, impelled by growing health awareness in the region.

Medline Industries, LP, Eli Lilly and Company, Bausch & Lomb Incorporated, Sun Pharmaceutical Industries Ltd., Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying